Jacques Touchon, MD, PhD, University Hospital of Montpellier, Montpellier, France, and co-founder of the Clinical Trials on Alzheimer’s Disease Congress (CTAD), presents some of the highlights from CTAD 2022. Notably, he mentions lecanemab which has now received approval from the US Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease (AD) in the US. From the data presented at CTAD 2022, lecanemab slowed cognitive decline in patients with early AD by 27% over an 18-month period – the first of its kind to do so. Prof. Touchon also noticed a theme of moving beyond amyloid and tau to create a more holistic approach to Alzheimer’s treatment. Lastly, he highlights the progress made in AD biomarkers, particularly in plasma biomarkers, the effect of which would improve clinical care by reducing the need for invasive spinal taps or expensive PET scans. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
